// App-Quantinova.ai

675 : TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Researchers

Presenter

  • Irene Brana

Principal Investigators

  • Valerii Cheshuk

  • Claus Andrup Kristensen

  • Maria Eugenia Ortega

  • Brieuc Sautois

  • Antonio Lopez-Pousa

  • Judith Christian

  • Willem Lybaert

  • Julio Peguero

  • John Park

  • Robert Metcalf

  • Lisle Nabell

  • Bernard Doger de Spéville

  • Jordi Rubió Casadevall

  • Ainara Soria Rivas

  • Martin Forster

  • Frederic Triebel

Medical Centers

  • Institut Català d’Oncologia – Hospital, Girona, Spain

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Oncology Consultants PA, Houston, TX

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • START Madrid, CIOCC, Madrid, Spain

  • Nottingham University hospital, U.K., Nottingham,

  • Macquarie University Hospital, Sydney, Australia

  • University of Alabama at Birmingham, Birmingham, AL

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Rigshospitalet, Copenhagen, Denmark

  • ARENSIA Exploratory Medicine LLC, Kyiv, Ukraine

  • Centre Hospitalier Universitaire (CHU), Liège, Belgium

  • Immutep S.A.S., Chatenay Malabry, France

  • UCL Cancer Institute; University College London Hospitals NHS Foundation – The Harley Street Clinic, London, UK

  • VITAZ, Sint-Niklaas, Belgium

Locations

  • Spain

  • United States

  • United Kingdom

  • Australia

  • Denmark

  • Ukraine

  • Belgium

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • EDP 202

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Immutep

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved